Carisma Therapeutics, Inc.

NasdaqGM:CARM Stock Report

Market Cap: US$35.5m

Carisma Therapeutics Balance Sheet Health

Financial Health criteria checks 1/6

Carisma Therapeutics has a total shareholder equity of $-11.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $42.1M and $53.2M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$28.13m
Equity-US$11.13m
Total liabilitiesUS$53.18m
Total assetsUS$42.06m

Recent financial health updates

Recent updates

Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

Sep 02
Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky

US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

May 12
US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results

Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

Apr 19
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%

We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Mar 26
We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate

Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

Jan 21
Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop

The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Dec 07
The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%

Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Nov 12
Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)

Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

Oct 05
Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation

We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Jun 15
We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely

Financial Position Analysis

Short Term Liabilities: CARM has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CARM has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CARM is debt free.

Reducing Debt: CARM's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CARM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CARM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 48.3% each year


Discover healthy companies